This company listing is no longer active
G2AB Stock Overview
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vifor Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.60 |
| 52 Week High | US$38.80 |
| 52 Week Low | US$28.00 |
| Beta | 1.04 |
| 1 Month Change | -1.92% |
| 3 Month Change | -10.53% |
| 1 Year Change | 4.79% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 26.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| G2AB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.7% | -2.5% | -2.6% |
| 1Y | 4.8% | -15.6% | 6.9% |
Return vs Industry: G2AB exceeded the German Pharmaceuticals industry which returned -14.9% over the past year.
Return vs Market: G2AB exceeded the German Market which returned -21.9% over the past year.
Price Volatility
| G2AB volatility | |
|---|---|
| G2AB Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G2AB has not had significant price volatility in the past 3 months.
Volatility Over Time: G2AB's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1872 | 2,200 | n/a | www.viforpharma.com |
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD) It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis.
Vifor Pharma AG Fundamentals Summary
| G2AB fundamental statistics | |
|---|---|
| Market cap | €10.16b |
| Earnings (TTM) | €147.94m |
| Revenue (TTM) | €1.83b |
15.9x
P/E Ratio1.3x
P/S RatioIs G2AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G2AB income statement (TTM) | |
|---|---|
| Revenue | CHF 1.81b |
| Cost of Revenue | CHF 671.80m |
| Gross Profit | CHF 1.14b |
| Other Expenses | CHF 993.70m |
| Earnings | CHF 146.60m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.26 |
| Gross Margin | 62.93% |
| Net Profit Margin | 8.09% |
| Debt/Equity Ratio | 13.6% |
How did G2AB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/26 04:19 |
| End of Day Share Price | 2022/12/23 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vifor Pharma AG is covered by 22 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Armelle Moulin | AlphaValue |
| Volker Bosse | Baader Helvea Equity Research |
| Jean-Philippe Bertschy | Bank Vontobel AG |